Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and framycetin

levofloxacin has been researched along with framycetin in 5 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(framycetin)		Trials
(framycetin)		Recent Studies (post-2010) (framycetin)
4,3465812,2098,151460653

Protein Interaction Comparison

ProteinTaxonomylevofloxacin (IC50)framycetin (IC50)
30S ribosomal protein S6Escherichia coli K-120.032
30S ribosomal protein S7Escherichia coli K-120.032
50S ribosomal protein L15Escherichia coli K-120.032
50S ribosomal protein L10Escherichia coli K-120.032
50S ribosomal protein L11Escherichia coli K-120.032
50S ribosomal protein L7/L12Escherichia coli K-120.032
50S ribosomal protein L19Escherichia coli K-120.032
50S ribosomal protein L1Escherichia coli K-120.032
50S ribosomal protein L20Escherichia coli K-120.032
50S ribosomal protein L27Escherichia coli K-120.032
50S ribosomal protein L28Escherichia coli K-120.032
50S ribosomal protein L29Escherichia coli K-120.032
50S ribosomal protein L31Escherichia coli K-120.032
50S ribosomal protein L31 type BEscherichia coli K-120.032
50S ribosomal protein L32Escherichia coli K-120.032
50S ribosomal protein L33Escherichia coli K-120.032
50S ribosomal protein L34Escherichia coli K-120.032
50S ribosomal protein L35Escherichia coli K-120.032
50S ribosomal protein L36Escherichia coli K-120.032
30S ribosomal protein S10Escherichia coli K-120.032
30S ribosomal protein S11Escherichia coli K-120.032
30S ribosomal protein S12Escherichia coli K-120.032
30S ribosomal protein S13Escherichia coli K-120.032
30S ribosomal protein S16Escherichia coli K-120.032
30S ribosomal protein S18Escherichia coli K-120.032
30S ribosomal protein S19Escherichia coli K-120.032
30S ribosomal protein S20Escherichia coli K-120.032
30S ribosomal protein S2Escherichia coli K-120.032
30S ribosomal protein S3Escherichia coli K-120.032
30S ribosomal protein S4Escherichia coli K-120.032
30S ribosomal protein S5Escherichia coli K-120.032
30S ribosomal protein S8Escherichia coli K-120.032
30S ribosomal protein S9Escherichia coli K-120.032
50S ribosomal protein L13Escherichia coli K-120.032
50S ribosomal protein L14Escherichia coli K-120.032
50S ribosomal protein L16Escherichia coli K-120.032
50S ribosomal protein L23Escherichia coli K-120.032
30S ribosomal protein S15Escherichia coli K-120.032
50S ribosomal protein L17Escherichia coli K-120.032
50S ribosomal protein L21Escherichia coli K-120.032
50S ribosomal protein L30Escherichia coli K-120.032
50S ribosomal protein L6Escherichia coli K-120.032
30S ribosomal protein S14Escherichia coli K-120.032
30S ribosomal protein S17Escherichia coli K-120.032
30S ribosomal protein S1Escherichia coli K-120.032
50S ribosomal protein L18Escherichia coli K-120.032
50S ribosomal protein L2Escherichia coli K-120.032
50S ribosomal protein L3Escherichia coli K-120.032
50S ribosomal protein L24Escherichia coli K-120.032
50S ribosomal protein L4Escherichia coli K-120.032
50S ribosomal protein L22Escherichia coli K-120.032
50S ribosomal protein L5Escherichia coli K-120.032
30S ribosomal protein S21Escherichia coli K-120.032
50S ribosomal protein L25Escherichia coli K-120.032
50S ribosomal protein L36 2Escherichia coli K-120.032

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Dewangan, RP; Ghosh, JK; Gupta, A; Habib, S; Mitra, K; Pant, G; Verma, DP; Verma, NK1
Mondschein, JI; Patel, S; Soulen, MC; Tuite, CM1
Bhamare, P; Dunman, PM; Johnson, W; Kinn, B; Laskey, E; Mei, JA; Nolin, L; Stalker, C; Wozniak, RAF1

Other Studies

5 other study(ies) available for levofloxacin and framycetin

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Spermine-Conjugated Short Proline-Rich Lipopeptides as Broad-Spectrum Intracellular Targeting Antibacterial Agents.
    Journal of medicinal chemistry, 2022, 04-14, Volume: 65, Issue:7

    Topics: Animals; Anti-Bacterial Agents; Bacteria; Escherichia coli; Lipopeptides; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Proline; Spermine; Staphylococcus aureus

2022
Effectiveness of an aggressive antibiotic regimen for chemoembolization in patients with previous biliary intervention.
    Journal of vascular and interventional radiology : JVIR, 2006, Volume: 17, Issue:12

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Biliary Tract Diseases; Case-Control Studies; Chemoembolization, Therapeutic; Drainage; Drug Therapy, Combination; Erythromycin; Humans; Levofloxacin; Liver Abscess; Liver Function Tests; Metronidazole; Neomycin; Ofloxacin; Retrospective Studies; Risk Factors; Stents

2006
Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates.
    Translational vision science & technology, 2022, 05-02, Volume: 11, Issue:5

    Topics: Anti-Bacterial Agents; Bacitracin; Drug Combinations; Erythromycin; Framycetin; Humans; Keratitis; Levofloxacin; Moxifloxacin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Tobramycin; Trimethoprim

2022